PharmiWeb.com - Global Pharma News & Resources

Today Stories

Cancer cells have to escape from the scaffolding that surrounds tumours – a structure called the extracellular matrix – in order to spread Researchers discovered that the layout of the matrix drives cancer cells to change their shape, increasing their ability to spread Patients with melanoma tumours with these features had shorter survival times The findings could help doctors spot which tumours are likely to be aggressive and cause metastatic cancer This opens new avenues for treating cancer before it spreads – by targeting the surroundings of the tumour, instead of the cancer cell itself Scientists have discovered a new way to predict which tumours will become aggressive before they metastasise and spread around the body. New research, published in Nature Communications, reveals how ca…
Sandwich, Kent, UK / 13 February 2025 /  Eleven early-stage companies working in oncology have started ‘Discovery Spark’, a free seven week development programme  hosted by leading science and innovation campus Discovery Park, in Sandwich, Kent. Designed to offer start-ups the skills and tools to lay healthy foundations in their business, refine their commercial strategy and achieve investor readiness, all 11 businesses will be put through their paces to enable future success and growth. Supported by Capital Enterprise Network, Cancer Tech Accelerator, NHS Kent and Medway Cancer Alliance and the University of Kent, Discovery Park’s latest Discovery Spark programme has an oncology theme. The 11 entrepreneurial businesses securing a coveted spot on this cohort and looking to advance their or…
The company, with two endocrinology products approved by both the European Medicines Agency (EMA) and the U.S. Food & Drug Administration (FDA), is developing additional endocrinology and oncology therapies, and has formed strategic partnerships in other indications and markets. The development of these drugs is based on the innovative TransCon® technology platform, which combines the efficacy of the parent drug, whose biology is known, with the benefits of prodrug and a sustained release mechanisms. London, United Kingdom, February 6th 2024 – Ascendis Pharma UK, a subsidiary of the global biopharmaceutical company with a portfolio of products and product candidates specialising in rare endocrine diseases, has opened a UK office and appointed a senior management team led by UK Genera…
The Apex is the first phase of a one million sq ft of purpose-built life sciences space in King’s Cross’ Knowledge Quarter The London BioScience Innovation Centre (LBIC) signed a lease on 39,000 sq ft or c. 35% of the space in the building The Francis Crick Institute is collaborating on 52,000 sq ft of space in the building 11 February 2025, London – Reef Group (“Reef”), the leading property development and investment specialist, and BlackRock Real Estate, have completed The Apex, the first laboratory building at TRIBECA, London’s largest purpose-built life science campus. The Apex is the first phase of the development and comprises over 110,000 sq ft of laboratory and office space, set over six floors. As a purpose-built life sciences campus, The Apex and subsequent phases of TRIBECA ha…
[Dublin, 10th February 2025] Global partner to pharmaceutical and medtech manufacturers, Uniphar, is expanding its international presence with the launch of three new, state-of-the-art facilities, strategically positioned across key global markets. The new facilities, located in Raleigh, USA, Lelystad, Netherlands, and Dublin, Ireland, reflect Uniphar’s commitment to enhancing its logistics and distribution capabilities within global pharmaceutical and healthcare sectors. With 57 years’ industry experience, Uniphar’s new facilities position the company to support pharmaceutical and biotech companies more effectively, offering comprehensive solutions that cover the entire product lifecycle. The new locations aim to ensure the timely delivery of critical therapies to patients worldwide, whil…
The research of BioMed X team EDC – Extrachromosomal DNA in Cancer – has uncovered critical insights into the mechanisms driving extrachromosomal DNA (ecDNA) formation and maintenance, offering potential avenues for novel cancer therapies. Heidelberg, Germany, February 6, 2025. BioMed X, a German independent research institute, announces the successful completion of its oncology research project in partnership with Merck. The data generated by this project has been acquired by Merck for further development, potentially leading to new therapeutic approaches in precision oncology. Launched in August 2022, the collaboration aimed to unravel the mechanisms behind the formation, propagation, and impact of ecDNA in cancer cells using state-of-the-art single-cell screening and spatial technolog…
Bracknell, UK. 4th February 2025: PharmiWeb.Jobs, the leading global life sciences job board, is excited to announce that the platform has now reached over 600,000 registered jobseekers, globally. This remarkable milestone signifies the team’s commitment to connecting life science professionals with the best career opportunities in the industry, whilst helping recruiters and hiring managers locate the top talent they need to drive their organisations forward. “Hitting 600,000 registered jobseekers is a huge milestone for PharmiWeb and a real testament to the trust life science professionals place in our platform,” said Vincent Lody, Managing Director of PharmiWeb. “Our goal has always been to connect talented people with the right opportunities, and it’s fantastic to see our community grow…
RESEARCH TRIANGLE PARK, N.C. – February 4, 2025 – IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2025 Fortune® World’s Most Admired Companies™ list. This is the fourth year in a row IQVIA has earned first place in the Health Care: Pharmacy and Other Services category, and the eighth consecutive year it has appeared on the list. Notably, IQVIA earned first place in its category on four key attributes — innovation, global competitiveness, people management and use of corporate assets. “We are deeply honored to be recognized for the fourth year in a row as number one on the World’s Most Admired Companies list for our category, and to be named to the list for the eighth consecuti…
Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancers With the closing of the transaction, BioNTech will expand its capabilities to develop, manufacture and commercialize novel BNT327 combinations and next-generation bispecific antibodies Biotheus will become a new indirect Chinese subsidiary of BioNTech, adding a local research and development hub and an advanced biologics manufacturing facility to the Company’s network MAINZ, Germany, February 3, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of Biotheus (“Biotheus”), a clinical-stage biotechnology company dedicated to the discovery and d…
Since 2021, Moderna has launched 23 clinical trials across 110 UK sites One in five of participants in industry-sponsored clinical research are enrolled in Moderna trials LONDON, UK—(ACCESS WIRE)— 31 January, 2024—Moderna, Inc. (NASDAQ:MRNA) has announced updates demonstrating substantial R&D investment and progress in the UK, two years since signing its strategic partnership with the UK government, at a milestone event at the Harwell Campus in Oxfordshire. The milestone event brought together stakeholders from across the UK life sciences ecosystem to mark the completion of the construction of the Moderna Innovation and Technology Centre (MITC) – the company’s state-of-the-art research, development and manufacturing facility. Subject to licensure, the first product manufactured at scal…
Enterprise Ireland grant awarded to ICON to further enhance artificial intelligence capabilities Dublin, Ireland – 30 January 2025 – ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portfolio of artificial intelligence (AI) tools that deliver efficiencies across the clinical trial process, including study startup, document management, resource forecasting and metrics reporting.  ICON has invested significantly in its AI and digital capabilities through the establishment of its AI Centre of Excellence. The centre, which comprises a dedicated team of data scientists, engineers and domain experts, is responsible for developing and deploying AI solutions that accelerat…
BURLINGTON, N.C. (January 29, 2025) – Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has once again been named to FORTUNE® magazine's 2025 list of the World’s Most Admired Companies,™ a recognition of the most respected and reputable companies globally. “We are proud to once again be named to FORTUNE’s World's Most Admired Companies list,” said Adam Schechter, chairman and CEO of Labcorp. “This honor reflects the continuous hard work and commitment of our employees to help us advance our mission to improve health and improve lives around the world.”   Labcorp ranked second in the “Healthcare: Pharmacy and Other Services” category, up from fourth place in 2024, scoring top marks in quality of management, financial soundness, long-term investment and…
Basel, 29 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Wafaa Mamilli (1967) will join the company as Chief Digital Technology Officer (CDTO), reporting to Group CEO, Thomas Schinecker, and will become a member of the enlarged Corporate Executive Committee starting 10 February 2025.  She will be based at Genentech in South San Francisco. In this new role, she will take over the worldwide responsibility for the Informatics function for the Roche Group from Alan Hippe, who currently has the dual role of Chief Financial Officer (CFO) and Chief Informatics Officer (CIO).  With our ambitions to transform our business with digital solutions and through enterprise-wide use of artificial intelligence, this is the right moment to split the two roles and ensure dedicated foc…
New next generation sequencing-based proteomics kits designed to integrate with multiple NGS platforms, eliminating the need for new instrumentation or specialized expertise UPPSALA, Sweden--(BUSINESS WIRE)-- Thermo Fisher Scientific, the world leader in serving science, today announced the introduction of Olink® Reveal, setting a new standard for affordable, high-plex proteomics that enables researchers to identify circulating biomarkers for a range of applications with reduced cost and set up requirements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250126428090/en/ New Olink Reveal next generation sequencing-based proteomics kits are designed to integrate with multiple NGS platforms, eliminating the need for new instrumen…
Collaboration unites GSK and Oxford’s complementary expertise in the science of the immune system, vaccines and cancer biology GSK to invest up to £50 million in collaboration to generate key insights on how cancer develops that could inform future development of cancer vaccines Programme adds to existing relationship, including the ongoing GSK-Oxford Institute of Molecular and Computational Medicine GSK plc (LSE/NYSE: GSK) and the University of Oxford (Oxford) today announced that they have entered a new research collaboration focused on the potential of cancer prevention through vaccination. The GSK-Oxford Cancer Immuno-Prevention Programme will conduct translational research, exploring precancer biology to generate key insights on how cancer develops in humans that could inform new…
Researchers at Karolinska Institutet and the Astrid Lindgren Children’s Hospital in Sweden have determined how children’s immune systems react to different kinds of cancer depending on their age. The study, which is published in the journal Cell, reveals significant differences between the immune response of children and adults, and has the potential to lead to new tailored treatments for children with cancer. “The activation of the immune system is crucial to our ability to fight cancer, but differs between children and adults,” says Petter Brodin, professor of paediatric immunology at the Department of Women’s and Children’s Health, Karolinska Institutet, and paediatrician at the Astrid Lindgren Children’s Hospital, Karolinska University Hospital. “If we’re to properly treat childhood ca…
Opella reaches study milestone for Cialis Paris, January 21, 2025. Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its planned actual use trial (AUT) to support the switch of Cialis (tadalafil) from a prescription to an over-the-counter medicine. This decision allows for the initiation of the AUT and makes Cialis the first PDE-5 inhibitor to achieve this milestone. AUTs evaluate the use of the medicine under real-world conditions to identify any issues that have not previously been identified and to confirm that consumers can self-diagnose and treat themselves appropriately without the help of a healthcare provider. Julie Van OngevallePresident and CEO, Opella“We are pleased that the FDA has completed the…
The data uncover broad optimism as well as stark regional disparities and cultural obstacles in the West that must be addressed to increase public acceptance of breakthrough innovations / More than 13,000 people surveyed in 13 countries representing every continent except Antarctica / The survey explored the public’s perceptions of cell and gene therapies, AI in medicine, new genomic techniques (NGTs) in agriculture, and cultivated meat Berlin, Germany, January 20, 2025 – As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch of one of the largest surveys examining global public sentiment towards transformative technology. The field work was con…
German research institute BioMed X started a new partnership with Daiichi Sankyo, a Japanese pharmaceutical company, to advance the development of bi- and multi-specific biologics for treating solid tumors. Heidelberg, Germany, January 14, 2025. BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new collaboration with Daiichi Sankyo Co., Ltd., a global pharmaceutical company headquartered in Japan. This collaboration marks the start of a cutting-edge initiative to explore innovative approaches in cancer treatment using multi-specific biologics. The new project, entitled “New Strategies for Targeting of Solid Tumors with Multi-Specific Biologics (MTT; Multi-Specific Targeting of Tumors)”, will be hosted at the BioMed X Inst…
RESEARCH TRIANGLE PARK, N.C. – January 13, 2025 – IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights, and healthcare intelligence, today announced a strategic collaboration with NVIDIA to help realize the potential of AI in healthcare and life sciences.  The healthcare and life sciences industries generate vast amounts of data, representing significant potential for AI-powered solutions. This collaboration between IQVIA and NVIDIA will help accelerate IQVIA Healthcare-grade AI™, enabling new levels of agentic automation of complex and time-consuming workflows across the therapeutic life cycle with the precision, scalability, and trust required by IQVIA’s customers. IQVIA has been leading in the responsible use of AI, ensuring that its AI-powered…